Ascendis Pharma A/S

NasdaqGS ASND

Ascendis Pharma A/S Revenue Per Share for the year ending December 31, 2023: USD 5.23

Ascendis Pharma A/S Revenue Per Share is USD 5.23 for the year ending December 31, 2023, a 435.61% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Ascendis Pharma A/S Revenue Per Share for the year ending December 31, 2022 was USD 0.98, a 504.06% change year over year.
Ascendis Pharma A/S Revenue Per Share for the year ending December 31, 2021 was USD 0.16, a -3.66% change year over year.
Ascendis Pharma A/S Revenue Per Share for the year ending December 31, 2020 was USD 0.17, a -48.01% change year over year.
Ascendis Pharma A/S Revenue Per Share for the year ending December 31, 2019 was USD 0.32, a 9.50% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

NasdaqGS: ASND

Ascendis Pharma A/S

CEO	Mr. Jan Moller Mikkelsen
IPO Date	Jan. 28, 2015
Location	Denmark
Headquarters	Tuborg Boulevard 12
Employees	879
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Key trends

Past 5 years